Semaglutide (Wegovy)

Description

Semaglutide (Wegovy) In Pakistan

Semaglutide (Wegovy) In Pakistan 2.4 mg injection is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight control in adults with a baseline body mass index (BMI) of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).

Wegovy™ contains semaglutide and should not be co-administered with other semaglutide-containing products or any GLP-1 receptor agonist.
The safety and effectiveness of Wegovy™ in combination with other products intended for weight loss, including prescription medications, over-the-counter medications, and herbal preparations, have not been established.

Semaglutide (Wegovy) Buy Now

Wegovy has not been studied in patients with a history of pancreatitis. Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior severe hypersensitivity reaction to semaglutide or any of the excipients of Wegovy™. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with semaglutide.
Warnings and precautions
Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or if thyroid nodules are noted on physical examination or neck imaging.

Semaglutide (Wegovy) Free Delivery

Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy™ in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including severe, persistent abdominal pain, sometimes radiating to the back, that may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue

Wegovy™ immediately, and if acute pancreatitis is confirmed, do not restart. Acute Gallbladder Disease: In clinical trials, 1.6% of Wegovy™ patients and 0.7% of placebo patients reported cholelithiasis. Cholecystitis was reported by 0.6% of Wegovy™ patients and 0.2% of placebo patients. Substantial or rapid weight loss may increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was higher in Wegovy™-treated patients than in placebo-treated patients, even after accounting for degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated